NMTC / NeuroOne Medical Technologies Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 18, 2025 NeuroOne Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 18, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpor

NeuroOne Medical Technologies Corporation Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-279871 Prospectus Supplement (To the Prospectus Supplements dated April 3, 2025 and August 16, 2024) (To the Prospectus dated August 16, 2024) NeuroOne Medical Technologies Corporation $6,750,000 Common Stock This prospectus supplement supplements the prospectus supplements dated August 16, 2024 and April 3, 2025 (the “Prior ATM Prospectus Supp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2025 NeuroOne Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpor

Second Amendment to NeuroOne Medical Technologies Corporation 2021 Incentive Plan

Exhibit 10.1 SECOND AMENDMENT TO NEUROONE MEDICAL TECHNOLOGIES CORPORTAION 2021 INDUCEMENT PLAN The NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Plan”) is hereby amended in the following respects, effective November 9, 2023, in accordance with Section 2(b)(vi) of the Plan. The first sentence of Section 3(a) of the Plan is deleted in its entirety and replaced with the follow

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9% Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026

Exhibit 99.1 NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9% Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., August 14, 2025 - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐ TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2025 NeuroOne Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpor

Corporate Presentation April 2025 NASDAQ: NMTC 2 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities Exchange Act of 1934, as amended.

Exhibit 99.2 Corporate Presentation April 2025 NASDAQ: NMTC 2 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward – look ing statement that refl

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporati

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6% Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Fun

Exhibit 99.1 NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6% Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 - NeuroOne Me

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporatio

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) April 4, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporati

Underwriting Agreement, dated April 4, 2025, between NeuroOne Medical Technologies Corporation and Ladenburg Thalmann & Co. Inc. (incorporated by reference to Exhibit 1.1 on the Registrant’s Current Report on Form 8-K filed on April 7, 2025).

Exhibit 1.1 16,000,000 SHARES of Common Stock OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION UNDERWRITING AGREEMENT April 4, 2025 Ladenburg Thalmann & Co. Inc. As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: The undersigned, NeuroOne Medical Technologies Corpor

16,000,000 Shares NeuroOne Medical Technologies Corporation Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-279871 PROSPECTUS SUPPLEMENT (To Prospectus dated August 16, 2024) 16,000,000 Shares NeuroOne Medical Technologies Corporation Common Stock We are offering 16,000,000 shares of our common stock, par value $0.001 per share, in this offering. The public offering price for each share of common stock is $0.50. Our common stock is listed on The Nasd

SUBJECT TO COMPLETION, DATED APRIL 3, 2025

Filed Pursuant to Rule 424(b)(5) Registration No. 333-279871 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and

NeuroOne Medical Technologies Corporation Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-279871 Prospectus Supplement (To the Prospectus Supplement dated August 16, 2024 and Prospectus dated August 16, 2024) NeuroOne Medical Technologies Corporation Common Stock This prospectus supplement updates and amends certain information contained in the prospectus supplement dated August 16, 2024 (the “Original Supplement”), to the prospectu

As filed with the Securities and Exchange Commission on February 21, 2025

As filed with the Securities and Exchange Commission on February 21, 2025 Registration No.

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) NeuroOne Medical Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan

Exhibit 10.1 NEUROONE MEDICAL TECHNOLOGIES CORPORATION 2025 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: January 10, 2025 APPROVED BY THE STOCKHOLDERS: February 14, 2025 1. GENERAL. (a) Successor to and Continuation of Prior Plans. The Plan is the successor to and continuation of the Prior Plans. As of the Effective Date, (i) no additional awards may be granted under the Prior Plans; (

NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan Form of Restricted Stock Unit Grant Agreement

Exhibit 10.2 Standard RSU Package NEUROONE MEDICAL TECHNOLOGIES CORPORATION RSU AWARD GRANT NOTICE (2025 EQUITY INCENTIVE PLAN) NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other ju

NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan Form of Option Grant Agreement

Exhibit 10.3 Standard Stock Option Grant Package   NEUROONE MEDICAL TECHNOLOGIES CORPORATION STOCK OPTION GRANT NOTICE (2025 EQUITY INCENTIVE PLAN)   NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), pursuant to its 2025 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth b

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorp

JOINT FILING AGREEMENT

Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No.

NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

Exhibit 99.1 NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., February 12, 2025 - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 12, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2024 ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 3, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpo

NeuroOne® Regains Compliance with Nasdaq Listing Requirements

Exhibit 99.1 NeuroOne® Regains Compliance with Nasdaq Listing Requirements EDEN PRAIRIE, Minn., February 4, 2025 — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has regained compliance with the Nas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Letter to Shareholders, dated January 14, 2025.

Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpor

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpo

NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M

Exhibit 99.1 NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue Management to Host Virtual Investor Webinar Today at 11:00 a.m. Eastern Time EDEN PRAIRIE, Minn., January 10, 2025 - N

Investor Presentation January 2025 NASDAQ: NMTC 2 Caution: Federal law restricts this device to sale by or on the order of a physician. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of Section

Exhibit 99.2 Investor Presentation January 2025 NASDAQ: NMTC 2 Caution: Federal law restricts this device to sale by or on the order of a physician. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.______)

PRE 14A 1 ea0226835-pre14aneuroone.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use

Insider Trading Policy

Exhibit 19.1 NeuroOne Medical Technologies Corporation Insider Trading Compliance Policy Effective June 20, 2023 This Insider Trading Compliance Policy (this “Policy”) consists of four sections: Section I provides an overview; Section II sets forth the policies of NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”) prohibiting insider trading; Section III explains ins

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 17, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorp

NeuroOne Medical Technologies Corporation Policy for the Recovery of Erroneously Awarded Compensation

Exhibit 97.1 NeuroOne Medical Technologies Corporation Policy for the Recovery of Erroneously Awarded Compensation Adopted and approved on November 9, 2023 and Effective as of November 9, 2023 1. Purpose. The Board of Directors (the “Board”) of NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”) believes that it is in the best interests of the Company and its stockhol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 ☐ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.

Subsidiaries of the Registrant

Exhibit 21.1 LIST OF SUBSIDIARIES None.

Non-Employee Director Compensation Policy

Exhibit 10.9 NeuroOne Medical Technologies Corporation Amended and Restated Non-Employee Director Compensation Policy Effective Date: October 1, 2024 On August 9, 2024, the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), approved the following amended and restated com

NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025

Exhibit 99.1 NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025 Company’s Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., December 17, 2024 - NeuroOne Medical Technolog

NMTC / NeuroOne Medical Technologies Corporation / LYTTON LAURENCE W Passive Investment

SC 13G/A 1 nmtc13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NeuroOne Medical Technologies Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 64130M209 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2024 NeuroOne Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpo

Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System

Exhibit 99.1 NeuroOne® Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS Markets Agreement expected to boost NeuroOne sales revenue and profitability EDEN PRAIRIE, Minn. – October 31, 2024 (GLOBE NEWSWIRE) – NeuroOne Medical Technologies Co

Amended and Restated Exclusive Development and Distribution Agreement, dated October 25, 2024, by and between NeuroOne and Zimmer.

Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is of the type that the Company treats as private or confidential. Double asterisks denote omissions. amended and restated EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT This Amended and Restated Exclusive Development and Distribution Agreement (this “Agreement”) is entered

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 25, 2024 NeuroOne Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 25, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpo

First Amendment to Offer Letter between the Company and Steve Mertens.

Exhibit 10.4 fIRST AMENDMENT TO Offer letter THIS FIRST AMENDMENT TO OFFER LETTER (this “Amendment”) between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and Steve Mertens (the “Employee”) is entered into and made effective as of September 9, 2024 (the “Amendment Date”). Recitals Whereas, on March 6, 2019, the Company and the Employee entered into an Offer Let

First Amendment to Offer Letter between the Company and Christopher Volker.

Exhibit 10.3 fIRST AMENDMENT TO Offer letter THIS FIRST AMENDMENT TO OFFER LETTER (this “Amendment”) between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and Christopher R. Volker (the “Employee”) is entered into and made effective as of September 9, 2024 (the “Amendment Date”). Recitals Whereas, on November 10, 2023, the Company and the Employee entered into

First Amendment to Offer Letter between the Company and Ronald McClurg.

EXHIBIT 10.2 fIRST AMENDMENT TO Offer letter THIS FIRST AMENDMENT TO OFFER LETTER (this “Amendment”) between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and Ronald McClurg (the “Employee”) is entered into and made effective as of September 9, 2024 (the “Amendment Date”). Recitals Whereas, on January 1, 2021, the Company and the Employee entered into an Offer

First Amendment to Employment Agreement between NeuroOne Medical Technologies Corporation and David A. Rosa dated September 9, 2024 (incorporated by reference to Exhibit 10.1 on the Registrant’s Current Report on Form 8-K filed on September 13, 2024)

Exhibit 10.1 fIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and David Rosa (the “Executive”) is entered into and made effective as of September 9, 2024 (the “Amendment Date”). Recitals Whereas, on August 4, 2017, the Company and the Executive entered i

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 9, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorp

September 12, 2024

September 12, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Jane Park Re: NeuroOne Medical Technologies Corporation Registration Statement on Form S-3 File No. 333-281881 Acceleration Request Requested Date: September 13, 2024 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 46

As filed with the U.S. Securities and Exchange Commission on September 12, 2024

As filed with the U.S. Securities and Exchange Commission on September 12, 2024 Registration No. 333-281881 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 27-0863354 (State or other jur

Fee Letter with Growth Opportunities Funding LLC, dated August 2, 2024.

Exhibit 10.3 NeuroOne Medical Technologies Corporation Attention: Dave Rosa, Chief Executive Officer 7599 Anagram Drive Eden Prairie, MN 55344 August 2, 2024 Ladies and Gentlemen: Reference is hereby made to that certain Loan and Security Agreement, dated as of August 2, 2024 (as may be amended, modified, supplemented or restated from time to time, the “Loan Agreement”), by and between GROWTH OPPO

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) NeuroOne Medical Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering price Per Share(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, par value $0.

As filed with the U.S. Securities and Exchange Commission on August 30, 2024

As filed with the U.S. Securities and Exchange Commission on August 30, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 27-0863354 (State or other jurisdiction of incorporation o

D

X0708 D LIVE 0001500198 NEUROONE MEDICAL TECHNOLOGIES Corp 7599 ANAGRAM DR EDEN PRAIRIE MN MINNESOTA 55344 (952) 426-1383 DELAWARE None Original Source Entertainment, Inc.

NeuroOne Medical Technologies Corporation Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-279871 Prospectus Supplement (to Prospectus dated August 16, 2024) $4,700,000 NeuroOne Medical Technologies Corporation Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock having an aggregate offering price of up to $4,700,000 from time to time pursuant to a Capital on Demand™ Sales Agreement d

August 15, 2024

August 15, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Benjamin Richie Re: NeuroOne Medical Technologies Corporation Registration Statement on Form S-3 File No. 333-279871 Acceleration Request Requested Date: August 16, 2024 Requested Time: 4:05 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 46

First Amendment to Lease Agreement, dated May 20, 2024, by and between Biynah Cleveland, LLC, BIP Cleveland LLC, Edenvale Investors, LLC and the Company.

Exhibit 10.1 FIRST AMENDMENT TO LEASE AGREEMENT This FIRST Amendment to Lease Agreement (this “Amendment”) is made as of the 20th day of May, 2024 (the “Effective Date”) by and between BIYNAH CLEVELAND, LLC, a Delaware limited liability company, BIP CLEVELAND, LLC, a Delaware limited liability company, and EDENVALE INVESTORS, LLC, a Delaware limited liability company (collectively, “Landlord”), an

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpor

NeuroOne Medical Technologies Corporation Condensed Balance Sheets

Exhibit 99.1 NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., August 14, 2024 (GlobeNewswire) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today anno

As filed with the Securities and Exchange Commission on August 14, 2024

As filed with the Securities and Exchange Commission on August 14, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

Form of Securities Purchase Agreement, dated August 1, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on August 7, 2024).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 1, 2024, between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). Recitals Whereas, on the terms and

Loan and Security Agreement, dated as of August 2, 2024, by and between the Company and Growth Opportunity Funding, LLC (incorporated by reference to Exhibit 10.2 on the Registrant’s Current Report on Form 8-K filed on August 7, 2024)

Exhibit 10.2 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”), dated August 2, 2024, is made by and between Growth Opportunity Funding, LLC, a Delaware limited liability company (the “Lender”), and NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Borrower”). In consideration of the mutual covenants and promises contained herein, and for other g

Form of Debt Facility Financing Warrant.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED

Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on August 7, 2024).

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpora

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 11, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporat

Amended and Restated Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant’s Current Report on Form 8-K filed on June 21, 2024

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation shall be fixed in the Certificate of Incorporation (as amended, the “Certificate of Incorporation”). Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 20, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporat

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.10 NEUROONE MEDICAL TECHNOLOGIES CORPORATION AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and [●], a [corpo

Form of Common Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.8 NEUROONE MEDICAL TECHNOLOGIES CORPORATION AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT(this “Agreement”), dated as of [●], between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and [●], a [corporation] [na

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) NeuroOne Medical Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to be Paid Equity Debt Other Unallocated (Universal) Shelf Common Stock, par value $0.

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.9 NEUROONE MEDICAL TECHNOLOGIES CORPORATION AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and [●], a [corpor

Form of Indenture, between the Registrant and one or more trustees to be named.

Exhibit 4.6 NEUROONE MEDICAL TECHNOLOGIES CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’s Ce

As filed with the Securities and Exchange Commission on May 31, 2024

As filed with the Securities and Exchange Commission on May 31, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporati

NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Exhibit 99.1 NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., May 14, 2024 (GlobeNewswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announ

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 26, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpora

Initiates Limited Commercial Launch of OneRF™ Ablation System

Exhibit 99.1 NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control Limited commercial launch initiated earlier than expected EDEN PRAIRIE, Minn. – March 26, 2024 (GLOBE NEWSWIRE) – NeuroOne Medical Tec

NASDAQ: NMTC NeuroOne ® Medical Technologies Corporation March 2024 3 Investment Highlights Received FDA (510k) clearance for OneRF Ablation system in December 2023; for use with EVO sEEG ® electrodes to treat neurologic conditions Strategy to access

Exhibit 99.1 NASDAQ: NMTC NeuroOne ® Medical Technologies Corporation March 2024 2 Safe Harbor Statements This presentation and any information included in this presentation are strictly confidential and should not be discussed outside of your organization. This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities and shall not constitute an offer,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 14, 2024 NeuroOne Medical T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 14, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpora

NMTC / NeuroOne Medical Technologies Corporation / Nantahala Capital Management, LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NeuroOne Medical Technologies Corporation (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 64130M209 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design

NeuroOne Medical Technologies Corporation Balance Sheets

Exhibit 99.1 NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., February 13, 2024 (GlobeNewswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2023 ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 13, 2024 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorp

As filed with the Securities and Exchange Commission on January 31, 2024

As filed with the Securities and Exchange Commission on January 31, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) NeuroOne Medical Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering price Per Unit Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.______)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A ––––––––––––––––––––––––––––––– Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt

NMTC / NeuroOne Medical Technologies Corporation / LYTTON LAURENCE W Passive Investment

SC 13G 1 nmtc.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NeuroOne Medical Technologies Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 64130M209 (CUSIP Number) December 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr

Up to $9,300,000 NeuroOne Medical Technologies Corporation Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-256830 Prospectus Supplement (To the Prospectus Supplements dated December 1, 2023 and December 21, 2022, and Prospectus dated June 14, 2021) Up to $9,300,000 NeuroOne Medical Technologies Corporation Common Stock This prospectus supplement updates and amends certain information contained in the prospectus supplements dated December 21, 2022 (t

As filed with the Securities and Exchange Commission on December 15, 2023

As filed with the Securities and Exchange Commission on December 15, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) NeuroOne Medical Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering price Per Unit Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

Subsidiaries of the Registrant

Exhibit 21.1 None.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.

NeuroOne Medical Technologies Corporation Policy for the Recovery of Erroneously Awarded Compensation

Exhibit 97.1 NeuroOne Medical Technologies Corporation Policy for the Recovery of Erroneously Awarded Compensation Adopted and approved on November 9, 2023 and Effective as of November 9, 2023 1. Purpose. The Board of Directors (the “Board”) OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION, a Delaware corporation (the “Company”) believes that it is in the best interests of the Company and its stockhol

NeuroOne Medical Technologies Corporation Balance Sheets

Exhibit 99.1 NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., December 14, 2023 (GlobeNewswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 14, 2023 NeuroOne Medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 14, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorp

Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System

Exhibit 99.1 NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System First FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control; Marks the Company’s third FDA 510(k)-cleared device Potential for transformative improvement in neurosurgery procedures; Company targets c

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 11, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-40439 27-0863354 (State or other jurisdiction of incorp

Up to $4,800,000 NeuroOne Medical Technologies Corporation Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-256830 Prospectus Supplement (To the Prospectus Supplement dated December 21, 2022 and Prospectus dated June 14, 2021) Up to $4,800,000 NeuroOne Medical Technologies Corporation Common Stock This prospectus supplement updates and amends certain information contained in the prospectus supplement dated December 21, 2022 (the “Original Supplement”

Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe

Exhibit 99.1 NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe Patent allowance strengthens IP portfolio and positions company in pursuing drug delivery using its neural probes EDEN PRAIRIE, Minn., November 16, 2023 (GlobeNewswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on im

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2023 NeuroOne Medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorp

Employment Offer Letter, dated as of November 10, 2023, by and between Christopher Volker and the Company

Exhibit 10.1 7599 Anagram Drive Eden Prairie, Minnesota 55344 November 10, 2023 Christopher R. Volker [Address] Dear Chris: We are pleased to offer you employment with NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”, “NeuroOne”, “we”, “us” or “our”). The terms of your offer of employment with the Company are as follows: Your initial position with us will be as Chie

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 NeuroOne Medical Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpo

First Amendment to NeuroOne Medical Technologies Corporation 2021 Inducement Plan (incorporated by reference to Exhibit 10.2 on the Registrant’s Current Report on Form 8-K filed on November 14, 2023)

Exhibit 10.2 FIRST AMENDMENT TO NEUROONE MEDICAL TECHNOLOGIES CORPORTAION 2021 INDUCEMENT PLAN The NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Plan”) is hereby amended in the following respects, effective November 9, 2023, in accordance with Section 2(b)(vi) of the Plan. The first sentence of Section 3(a) of the Plan is deleted in its entirety and replaced with the followi

Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Exhibit 99.1 NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., November 14, 2023 (GlobeNewswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“Neur

Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System

Exhibit 99.1 NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System Feedback from responses to FDA anticipated in 30 days Commercialization remains on track in first half of 2024 pending FDA clearance Product potential for transformative improvement in neurosurgery as first known sEEG-guided RF system that records and ablates nervous tissue with the added benefit of

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorpo

NeuroOne Medical Technologies Corporation Condensed Balance Sheets

Exhibit 99.1 NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., August 14, 2023 (GlobeNewswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today anno

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

NMTC / NeuroOne Medical Technologies Corp / MANCHESTER MANAGEMENT CO LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

NeuroOne Medical Technologies Corporation Announces Pricing of Public Offering of Common Stock

Exhibit 99.2 NeuroOne Medical Technologies Corporation Announces Pricing of Public Offering of Common Stock EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the pricing

Underwriting Agreement, dated July 24, 2023, between NeuroOne Medical Technologies Corporation and The Benchmark Company, LLC (incorporated by reference to Exhibit 1.1 on the Registrant’s Current Report on Form 8-K filed on July 27, 2023)

Exhibit 1.1 EXECUTION VERSION 5,250,000 Shares1 NEUROONE MEDICAL TECHNOLOGIES CORPORATION Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT July 24, 2023 The Benchmark Company, LLC 150 East 58th Street, 17th Floor New York New York 10155 Ladies and Gentlemen: NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”) proposes to sell to The Benchmark Company, L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported July 24, 2023 NeuroOne Medical Tech

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported July 24, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporatio

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

Exhibit 99.1 NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock EDEN PRAIRIE, Minn., July 24, 2023 (GLOBE NEWSWIRE) – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has c

5,250,000 Shares NeuroOne Medical Technologies Corporation Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-256830 PROSPECTUS SUPPLEMENT (To Prospectus dated June 14, 2021) 5,250,000 Shares NeuroOne Medical Technologies Corporation Common Stock We are offering 5,250,000 shares of our common stock, par value $0.001 per share, in this offering. The public offering price for each share of common stock is $1.00. Our common stock is listed on The Nasdaq C

SUBJECT TO COMPLETION, DATED JULY 24, 2023

Filed Pursuant to Rule 424(b)(5) Registration No. 333-256830 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the shares has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement is not an offer to sell the shares and it is not soliciting

$2,560,000 NeuroOne Medical Technologies Corporation Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-256830 Prospectus Supplement (To the Prospectus Supplement dated December 21, 2022 and Prospectus dated June 14, 2021) $2,560,000 NeuroOne Medical Technologies Corporation Common Stock This prospectus supplement updates and amends certain information contained in the prospectus supplement dated December 21, 2022 (the “Original Supplement”), to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2023 NeuroOne Medical Tec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporati

NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Exhibit 99.1 NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., May 11, 2023 (GlobeNewswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2023 NeuroOne Medical T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpora

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 10, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpora

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) NeuroOne Medical Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Newly Registered and Carry Forward Securities Fees to be Paid Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering price Per Unit Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

As filed with the Securities and Exchange Commission on February 22, 2023

As filed with the Securities and Exchange Commission on February 22, 2023 Registration No.

NeuroOne Medical Technologies Corporation Balance Sheets

Exhibit 99.1 NeuroOne® Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., February 14, 2023 (PR Newswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today anno

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2023 NeuroOne Medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorp

Corporate Fact Sheet, dated February 14, 2023

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2022 ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A ________________ Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.______)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpor

Capital on Demand™ Sales Agreement, dated December 21, 2022 between NeuroOne Medical Technologies Corporation and JonesTrading Institutional Services LLC (incorporated by reference to Exhibit 1.1 on the Registrant’s Annual Report on Form 10-K filed on December 22, 2022)

Exhibit 1.1 NEUROONE MEDICAL TECHNOLOGIES CORPORATION Common Stock ($0.001 par value per share) Capital on Demand™ Sales Agreement December 21, 2022 JonesTrading Institutional Services LLC 211 East 43rd Street, 15th Floor New York, NY 10017 Ladies and Gentlemen: NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTr

Subsidiaries of the Registrant

Exhibit 21.1 None.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 22, 2022 NeuroOne Medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 22, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorp

$14,500,000 NeuroOne Medical Technologies Corporation Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-256830 Prospectus Supplement (to Prospectus dated June 14, 2021) $14,500,000 NeuroOne Medical Technologies Corporation Common Stock We have entered into a Capital on Demand? Sales Agreement, or sales agreement, with JonesTrading Institutional Services LLC, or JonesTrading, relating to the sale of shares of our common stock offered by this prosp

NeuroOne Medical Technologies Corporation Balance Sheets (unaudited)

Exhibit 99.1 NeuroOne? Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results EDEN PRAIRIE, Minn., December 22, 2022 (PR Newswire) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; ?NeuroOne? or the ?Company?), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces financial resu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 12, 2022 NeuroOne Medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 12, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorp

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 25, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorpo

Receives FDA 510(k) Clearance to Market its Evo

Exhibit 99.1 NeuroOne? Receives FDA 510(k) Clearance to Market its Evo? sEEG System for Less than 30 Day Use Company focused on manufacturing ramp for commercialization in partnership with Zimmer Biomet EDEN PRAIRIE, Minn. ? October 25, 2022 - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options

FACT SHEET Fall 2022 Nasdaq: NMTC https://n1mtc.com Advancing Neuroscience One Neuron at a Time. NeuroOne Medical Technologies Corporation is a medical technology company focused on the development and commercialization of minimally invasive and high

Exhibit 99.1 FACT SHEET Fall 2022 Nasdaq: NMTC https://n1mtc.com Advancing Neuroscience One Neuron at a Time. NeuroOne Medical Technologies Corporation is a medical technology company focused on the development and commercialization of minimally invasive and high - definition/high - precision solutions for epilepsy, Parkinson?s disease, dystonia, essential tremors, and chronic pain due to failed b

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 14, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incor

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpor

Second Amendment to Exclusive Development and Distribution Agreement by and between the Company and Zimmer, Inc. dated June 28, 2022 (incorporated by reference to Exhibit 10.1 on the Registrant’s Quarterly Report on Form 10-Q filed on August 11, 2022)

Exhibit 10.1 SECOND AMENDMENT TO EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT THIS SECOND AMENDMENT TO EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT (this ?Amendment?) is made as of this 28th day of June, 2022, with an effective date of July 1, 2022 (?Effective Date?), between Zimmer, Inc., a Delaware corporation (?Zimmer?), and NeuroOne Medical Technologies Corporation, a Delaware corporat

2

Exhibit 99.1 NeuroOne? Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., August 11, 2022 (PR Newswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (?NeuroOne? or the ?Company?), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 ☐ TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 on the Registrant’s Quarterly Report on Form 10-Q filed on August 11, 2022)

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED

Third Amendment to Exclusive Development and Distribution Agreement by and between the Company and Zimmer, Inc. dated August 2, 2022 (incorporated by reference to Exhibit 10.2 on the Registrant’s Quarterly Report on Form 10-Q filed on August 11, 2022)

Exhibit 10.2 THIRD AMENDMENT TO EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT THIS THIRD AMENDMENT TO EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT (this ?Amendment?) is entered into as of August 2, 2022 (the ?Effective Date?), by and between Zimmer, Inc., a Delaware corporation (?Zimmer?), and NeuroOne Medical Technologies Corporation, a Delaware corporation (the ?Company?). Zimmer and the

Warrant to Purchase Common Stock

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED

Third Amendment to Exclusive Distribution and Development Agreement

Exhibit 10.1 THIRD AMENDMENT TO EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT THIS THIRD AMENDMENT TO EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT (this “Amendment”) is entered into as of August 2, 2022 (the “Effective Date”), by and between Zimmer, Inc., a Delaware corporation (“Zimmer”), and NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”). Zimmer and the

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 NeuroOne Medical Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpora

NeuroOne® Announces $3.5 Million Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode Amendment provides Zimmer Biomet with 350,000 warrants with exercise price of $3.00 per share

Exhibit 99.1 NeuroOne® Announces $3.5 Million Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode Amendment provides Zimmer Biomet with 350,000 warrants with exercise price of $3.00 per share EDEN PRAIRIE, Minn., August 3, 2022 (PR Newswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improvi

NeuroOne® Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders Letter recaps key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond

Exhibit 99.1 NeuroOne? Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders Letter recaps key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond EDEN PRAIRIE, Minn., June 2, 2022 (PR Newswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (?NeuroOne? or the ?Company?), a medical technology company focused on

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 31, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 ☐ TRANS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A (Amendment No.

NeuroOne Provides Evo

Exhibit 99.1 NeuroOne Provides Evo? sEEG Update The Evo? sEEG electrode 510(k) cleared for temporary (less than 24 hours) use remains in effect and the Company will explore the opportunity to market the device for intraoperative use. EDEN PRAIRIE, Minn., May 16, 2022 (PR Newswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (?NeuroOne? or the ?Company?), a medical technology company

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

2

Exhibit 99.1 NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., May 12, 2022 (PR Newswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (?NeuroOne? or the ?Company?), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 25, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2021 ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54716 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorp

NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Exhibit 99.1 NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., February 14, 2022 (PR Newswire) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announ

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 3, 2022 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorpo

As filed with the Securities and Exchange Commission on January 28, 2022

As filed with the Securities and Exchange Commission on January 28, 2022 Registration No.

Subsidiaries of the Registrant

Exhibit 21.1 None.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 15, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorp

Amendment to Exclusive Development and Distribution Agreement by and between the Company and Zimmer, Inc. dated January 6, 2021 (incorporated by reference to Exhibit 10.39 on the Registrant’s Annual Report on Form 10-K filed on December 15, 2021)

Exhibit 10.39 ZIMMER BIOMET Via Email January 6, 2021 NeuroOne Medical Technologies Corporation ATTN: Dave Rosa 7599 Anagram Drive Eden Prairie, MN 55344 [email protected] Dear Dave: As a follow-up to our recent discussions, this letter will confirm that the parties have agreed to extend the deadline for the "Design freeze for the SEEG Products" as set forth in Section 6.1(c)(i) of the Exclusive Dev

NeuroOne Reports Fourth Fiscal Quarter and Full Fiscal Year 2021 Financial Results and Provides Corporate Update

Exhibit 99.1 NeuroOne Reports Fourth Fiscal Quarter and Full Fiscal Year 2021 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., December 15, 2021 (PR Newswire) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; ?NeuroOne? or the ?Company?), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disord

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 ☐ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.

As filed with the Securities and Exchange Commission on November 23, 2021

As filed with the Securities and Exchange Commission on November 23, 2021 Registration No.

3,750,000 Shares NeuroOne Medical Technologies Corporation Common Stock

424B5 1 f424b51021neuroone.htm PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. 333-256830 PROSPECTUS SUPPLEMENT (To Prospectus dated June 14, 2021) 3,750,000 Shares NeuroOne Medical Technologies Corporation Common Stock We are offering 3,750,000 shares of our common stock, par value $0.001 per share, in this offering. The public offering price for each share of common stock is $3.20.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 13, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorpo

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

Exhibit 99.1 NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock EDEN PRAIRIE, MN., October 12, 2021 ? NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the ?Company?), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has commenced a propo

Underwriting Agreement, dated October 13, 2021, between NeuroOne Medical Technologies Corporation and Craig-Hallum Capital Group LLC (incorporated by reference to Exhibit 1.1 on the Registrant’s Current Report on Form 8-K filed on October 14, 2021)

Exhibit 1.1 Execution Version 3,750,000 Shares1 NEUROONE MEDICAL TECHNOLOGIES CORPORATION Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT October 13, 2021 Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Ladies and Gentlemen: NeuroOne Medical Technologies Corporation, a Delaware corporation (the ?Company?) proposes to sell to Craig-Hallu

NeuroOne Medical Technologies Corporation Announces Pricing of Public Offering of Common Stock

Exhibit 99.2 NeuroOne Medical Technologies Corporation Announces Pricing of Public Offering of Common Stock EDEN PRAIRIE, MN., October 13, 2021 ? NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the ?Company?), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the pricing of an underwrit

SUBJECT TO COMPLETION, DATED OCTOBER 13, 2021

Filed Pursuant to Rule 424(b)(5) Registration No. 333-256830 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the shares has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement is not an offer to sell the shares and it is not soliciting

NeuroOne Medical Technologies Corporation 2021 Inducement Plan (incorporated by reference to Exhibit 10.1 on the Registrant’s Current Report on Form 8-K filed on October 4, 2021)

Exhibit 10.1 NeuroOne Medical Technologies Corporation 2021 Inducement Plan Adopted by the Board of Directors: October 4, 2021 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 4, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorpor

NeuroOne Medical Technologies Corporation 2021 Inducement Plan Form of Option Grant Agreement (incorporated by reference to Exhibit 10.2 on the Registrant’s Current Report on Form 8-K filed on October 4, 2021)

Exhibit 10.2 NeuroOne Medical Technologies Corporation Stock Option Grant Notice (2021 Inducement Plan) NeuroOne Medical Technologies Corporation, a Delaware corporation (the ?Company?), pursuant to its 2021 Inducement Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorp

Medical Technologies Corporation Receives FDA 510(k) Clearance for its Evo

Exhibit 99.1 NeuroOne? Medical Technologies Corporation Receives FDA 510(k) Clearance for its Evo? sEEG Electrode Company?s second FDA 510(k) clearance received EDEN PRAIRIE, Minn. ? September 7, 2021 - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorpor

NeuroOne Reports Third Quarter Fiscal 2021 Financial Results and Corporate Update

Exhibit 99.1 NeuroOne Reports Third Quarter Fiscal 2021 Financial Results and Corporate Update EDEN PRAIRIE, Minn. - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; ?NeuroOne? or the ?Company?), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today financial results for the quarter ended Jun

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 ☐ TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54716 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 18, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorporat

Letter from BDO USA, LLP (incorporated by reference to Exhibit 16 on the Registrant’s Current Report on Form 8-K filed on June 24, 2021).

Exhibit 16 June 24, 2021 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on June 18, 2021, to be filed by our former client, NeuroOne Medical Technologies Corporation. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very

June 10, 2021

June 10, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Alan Campbell and Fredrick Philantrope Re: NeuroOne Medical Technologies Corporation Registration Statement on Form S-3 File No. 333-256830 Acceleration Request Requested Date: June 14, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen:

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 2, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorporati

As filed with the Securities and Exchange Commission on June 4, 2021

As filed with the Securities and Exchange Commission on June 4, 2021 Registration No.

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.10 NEUROONE MEDICAL TECHNOLOGIES CORPORATION AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between NeuroOne Medical Technologies Corporation, a Delaware corporation (the ?Company?), and [?], a [corpo

Form of Indenture, between the Registrant and one or more trustees to be named.

Exhibit 4.7 NEUROONE MEDICAL TECHNOLOGIES CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee

Form of Common Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.9 NEUROONE MEDICAL TECHNOLOGIES CORPORATION AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT(this ?Agreement?), dated as of [?], between NeuroOne Medical Technologies Corporation, a Delaware corporation (the ?Company?), and [?], a [corporation] [na

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.11 NEUROONE MEDICAL TECHNOLOGIES CORPORATION AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between NeuroOne Medical Technologies Corporation, a Delaware corporation (the ?Company?), and [?], a [corpo

NeuroOne Announces Approval for Nasdaq Capital Market Listing;Trading Expected to Commence Tomorrow May 26th, 2021 Under the Symbol NMTC

Exhibit 99.1 NeuroOne Announces Approval for Nasdaq Capital Market Listing;Trading Expected to Commence Tomorrow May 26th, 2021 Under the Symbol NMTC EDEN PRAIRIE, Minn. May 25th, 2021 /PRNewswire/ - NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neuro

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 25, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorporati

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 27-0863354 (State of incorporation or organization) (I.R.S. Employer Identification No.) 75

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54716 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

- DEFINITIVE PROXY STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant S Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) S Definitive Proxy State

Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant’s Current Report on Form 8-K filed on March 31, 2021)

EX-3.1 2 ea138690ex3-1neuroone.htm CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION. EXHIBIT 3.1 Certificate of Amendment to the Certificate of Incorporation of NeuroOne Medical Technologies Corporation NeuroOne Medical Technologies Corporation, a corporation organized and existing under and by virtue of the General Corporat

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorpora

NeuroOne Medical Technologies Corporation Announces Reverse Stock Split as Part of Uplisting Strategy to Major Exchange

EX-99.1 3 ea138690ex99-1neuroone.htm PRESS RELEASE DATED MARCH 31, 2021 ANNOUNCING THE REVERSE STOCK SPLIT. EXHIBIT 99.1 NeuroOne Medical Technologies Corporation Announces Reverse Stock Split as Part of Uplisting Strategy to Major Exchange Eden Prairie, MN – March 31, 2021– NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on im

NeuroOne Medical Technologies Corporation 12,500,000 Shares of Common Stock Offered by Selling Securityholders 12,500,000 Warrants Offered by Selling Securityholders 12,500,000 Shares of Common Stock Issuable upon Exercise of Resold Warrants

424B3 1 ea137258-424b3neuroone.htm PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-252951 NeuroOne Medical Technologies Corporation 12,500,000 Shares of Common Stock Offered by Selling Securityholders 12,500,000 Warrants Offered by Selling Securityholders 12,500,000 Shares of Common Stock Issuable upon Exercise of Resold Warrants This prospectus relates to the public offering by t

March 5, 2021

March 5, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Tim Buchmiller Re: NeuroOne Medical Technologies Corporation Registration Statement on Form S-1 File No. 333-252951 Acceleration Request Requested Date: March 8, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 und

- AMENDMENT NO. 1 TO FORM S-1

As filed with the Securities and Exchange Commission on March 4, 2021. Registration No. 333-252951 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 3841 27-0863354 (State or other jurisdi

NeuroOne Medical Technologies Corporation 7599 Anagram Drive Eden Prairie, Minnesota 55344

NeuroOne Medical Technologies Corporation 7599 Anagram Drive Eden Prairie, Minnesota 55344 March 4, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 23, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorp

NeuroOne Medical Technologies Corporation Announces Successful Completion of First Performance Milestone in Zimmer Biomet Agreement

EX-99.1 2 ea136246ex99-1neuromed.htm PRESS RELEASE DATED FEBRUARY 23, 2021 Exhibit 99.1 NeuroOne Medical Technologies Corporation Announces Successful Completion of First Performance Milestone in Zimmer Biomet Agreement Eden Prairie, MN – February 23, 2021– NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical c

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54716 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or Other Jurisdiction of Incorporation or Organization) (I.

Annual Report - AMENDMENT NO. 2 TO FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A (Amendment No.

Registration Statement - REGISTRATION STATEMENT

As filed with the Securities and Exchange Commission on February 10, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 3841 27-0863354 (State or other jurisdiction of (Primary Sta

Annual Report - AMENDMENT NO.1 TO FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A (Amendment No.

manchemansUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )*

manchemansUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Form of Common Stock and Warrant Purchase Agreement (incorporated by reference to Exhibit 10.1 on the Registrant’s Current Report on Form 8-K filed on January 15, 2021)

EX-10.1 3 ea133294ex10-1neuroone.htm FORM OF PURCHASE AGREEMENT Exhibit 10.1 NeuroOne Medical Technologies Corporation Common Stock and Warrant Purchase Agreement This Common Stock and Warrant Purchase Agreement (this “Agreement”) is made as of January 12, 2021, by and among NeuroOne Medical Technologies Corporation, a Delaware corporation, with its principal office at 7599 Anagram Drive, Eden Pra

NeuroOne Medical Technologies Corporation Announces Private Placement

EX-99.1 4 ea133294ex99-1neuroone.htm PRESS RELEASE DATED JANUARY 12, 2021 Exhibit 99.1 NeuroOne Medical Technologies Corporation Announces Private Placement Eden Prairie, MN – January 12, 2021 – NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, a

Form of Warrant (incorporated by reference to Exhibit 4.1 on the Registrant’s Current Report on Form 8-K filed on January 15, 2021).

Exhibit 4.1 FORM OF WARRANT NEITHER THE SECURITIES REPRESENTED HEREBY NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UN

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 12, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorpo

NeuroOne Medical Technologies Corporation Closes $12.5 Million Private Placement with Certain Prominent Institutional Investors, Advances Towards Nasdaq Uplisting

EX-99.2 5 ea133294ex99-2neuroone.htm PRESS RELEASE DATED JANUARY 15, 2021 Exhibit 99.2 NeuroOne Medical Technologies Corporation Closes $12.5 Million Private Placement with Certain Prominent Institutional Investors, Advances Towards Nasdaq Uplisting Eden Prairie, MN – January 15, 2021–NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company foc

Employment Offer Letter, dated as of January 1, 2021, by and between Ron McClurg and the Company (incorporated by reference to Exhibit 10.1 on the Registrant’s Current Report on Form 8-K filed on January 7, 2021)

EX-10.1 2 ea132820ex10-1neuroone.htm EMPLOYMENT OFFER LETTER, DATED AS OF JANUARY 1, 2021, BY AND BETWEEN RON MCCLURG AND THE COMPANY Exhibit 10.1 7599 Anagram Drive Eden Prairie, Minnesota 55344 January 1, 2021 Ron McClurg 3155 Olive Lane North Plymouth, Minnesota 55447 Dear Ron: We are pleased to offer you employment with NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Co

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 1, 2021 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorpor

NeuroOne Medical Technologies Corporation Appoints Ronald McClurg, Experienced Financial Industry Executive, as Chief Financial Officer

EX-99.1 3 ea132820ex99-1neuroone.htm PRESS RELEASE, DATED JANUARY 7, 2021 Exhibit 99.1 NeuroOne Medical Technologies Corporation Appoints Ronald McClurg, Experienced Financial Industry Executive, as Chief Financial Officer Eden Prairie, MN – January 7, 2021– NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options an

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54716 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0863354 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.

Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to Registrant’s Annual Report on Form 10-K filed December 9, 2020)

Exhibit 21.1 None.

PRELIMINARY PROSPECTUS NeuroOne Medical Technologies Corporation 7,927,902 Shares of Common Stock Offered by Selling Stockholders

Filed Pursuant to Rule 424(b)(3) Registration No. 333-232656 PRELIMINARY PROSPECTUS NeuroOne Medical Technologies Corporation 7,927,902 Shares of Common Stock Offered by Selling Stockholders This prospectus relates to the public offering of up to 7,927,902 shares of common stock of NeuroOne Medical Technologies Corporation (the “Company”) by the selling stockholders listed on page 6 (the “Selling

NeuroOne Medical Technologies Corporation Provides Commercialization Update for EVO Cortical Electrode

EX-99.1 2 ea127849ex99-1neuroone.htm PRESS RELEASE, DATED OCTOBER 6, 2020 Exhibit 99.1 NeuroOne Medical Technologies Corporation Provides Commercialization Update for EVO Cortical Electrode Eden Prairie, MN – October 6, 2020– NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering

Financial Statements and Exhibits, Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 6, 2020 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorpor

- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1

As filed with the Securities and Exchange Commission on September 29, 2020 Registration No.

PRELIMINARY PROSPECTUS NeuroOne Medical Technologies Corporation 11,517,808 Shares of Common Stock Offered by Selling Stockholders

Filed Pursuant to Rule 424(b)(3) Registration No. 333-244487 PRELIMINARY PROSPECTUS NeuroOne Medical Technologies Corporation 11,517,808 Shares of Common Stock Offered by Selling Stockholders This prospectus relates to the public offering of up to 11,517,808 shares of common stock of NeuroOne Medical Technologies Corporation (the “Company”) by the selling stockholders listed on page 9 (the “Sellin

Unregistered Sales of Equity Securities

8-K 1 ea126299-8kneuroone.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 31, 2020 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (

- AMENDMENT NO. 1 TO FORM S-1

S-1/A 1 ea125947-s1aneuroonemedical.htm AMENDMENT NO. 1 TO FORM S-1 As filed with the Securities and Exchange Commission on August 26, 2020. Registration No. 333-244487 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroOne Medical Technologies Corporation (Exact name of registrant as spec

-

August 27, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Ada D. Sarmento Re: NeuroOne Medical Technologies Corporation Registration Statement on Form S-1 File No. 333-244487 Acceleration Request Requested Date: August 28, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 46

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended June 30, 2020 -OR- ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 000-54716 NeuroOne Medical Te

Registration Statement - REGISTRATION STATEMENT

As filed with the Securities and Exchange Commission on August 11, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 3841 27-0863354 (State or other jurisdiction of (Primary Stand

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 28, 2020 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 000-54716 27-0863354 (State or other jurisdiction of incorporat

Securities Purchase Agreement, dated as of July 24, 2020, by and between the Company and the Purchaser listed thereto (incorporated by reference to Exhibit 10.1 on the Registrant’s Current Report on Form 8-K filed on August 3, 2020).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 28, 2020, between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). Recitals Whereas, on the terms and s

NeuroOne Medical Technologies Corporation Reduces Debt by $3.3 Million and Strengthens Balance Sheet Company Preparing for Commercialization of Thin Film Electrodes Technology

Exhibit 99.1 NeuroOne Medical Technologies Corporation Reduces Debt by $3.3 Million and Strengthens Balance Sheet Company Preparing for Commercialization of Thin Film Electrodes Technology Eden Prairie, MN – July 28, 2020 – NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering f